Article Text

Download PDFPDF
Renal and pulmonary effects of angiotensin converting enzyme inhibition in chronic hypoxic lung disease.
  1. R M Oliver,
  2. A J Peacock,
  3. J S Fleming,
  4. D G Waller
  1. Department of Medicine, Southampton General Hospital.


    The effects of 28 days' treatment with captopril or with placebo on renal and pulmonary function were evaluated in nine patients with stable pulmonary heart disease. Captopril (25 mg twice daily) caused a 17% rise in effective renal plasma flow but no change in glomerular filtration rate, resulting in a fall in filtration fraction likely to favour natriuresis. Captopril did not alter FEV1, lung volumes, or arterial oxygen or carbon dioxide tension.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.